[go: up one dir, main page]

WO2017050855A1 - Méthode de cotation pour prédire l'efficacité d'un traitement comprenant des anticorps monoclonaux anti-pd-1 et/ou anti-pd-l1 - Google Patents

Méthode de cotation pour prédire l'efficacité d'un traitement comprenant des anticorps monoclonaux anti-pd-1 et/ou anti-pd-l1 Download PDF

Info

Publication number
WO2017050855A1
WO2017050855A1 PCT/EP2016/072477 EP2016072477W WO2017050855A1 WO 2017050855 A1 WO2017050855 A1 WO 2017050855A1 EP 2016072477 W EP2016072477 W EP 2016072477W WO 2017050855 A1 WO2017050855 A1 WO 2017050855A1
Authority
WO
WIPO (PCT)
Prior art keywords
tumor
pla
patients
treatment
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2016/072477
Other languages
English (en)
Inventor
Isabelle GIRAULT
Stephan Vagner
Caroline Robert
Emilie LANOY
Matthieu TEXIER
Julien Adam
Shensi SHEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Gustave Roussy (IGR)
Original Assignee
Institut Gustave Roussy (IGR)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP15306470.4A external-priority patent/EP3147664A1/fr
Application filed by Institut Gustave Roussy (IGR) filed Critical Institut Gustave Roussy (IGR)
Publication of WO2017050855A1 publication Critical patent/WO2017050855A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H30/00—ICT specially adapted for the handling or processing of medical images
    • G16H30/40—ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Definitions

  • the present invention relates to a computer implemented method for assessing the efficiency of a treatment based on anti-PD-1 and/or anti-PD-Ll monoclonal antibodies.
  • Immunotherapy has been revolutionized by the concept of breaking tolerance. It represents a major paradigm shift that marks the beginning of a new era in treatment of cancer diseases.
  • the impact of the first checkpoint inhibitors, named "anti-CTLA-4" (cytotoxic T lymphocyte antigen-4) and "anti- PD-1/ anti-PD-Ll” (programmed death- 1 receptor and its ligand, PD-L1) is unprecedented.
  • advanced melanoma has been transformed from an incurable disease into a potentially curable disease and it is believed to have also a transversal impact throughout solid tumor oncology.
  • response rates are about 12% for anti-CTLA-4 and about 40% for anti-PD-1 , and are remarkably durable, hence their impact on survival.
  • anti-CTLA-4 (ipilimumabTM) was approved in 2011 and anti-PD-1 (pembrolimumabTM) in 2014.
  • Another anti-PD-1 antibody (nivolumabTM) has been recently approved based on phase III trial results in metastatic melanoma without BRAF mutation.
  • IpilimumabTM already has been evaluated in the adjuvant setting (European Organization for Research and Treatment of Cancer [EORTC] 18071) and shown to significantly improve recurrence-free survival in stage III patients at high risk of relapse.
  • An adjuvant trial to evaluate pembrolizumabTM in this population (EORTC 1325) was started in early 2015.
  • Treatments with anti-PD-1 or anti-PD-Ll monoclonal antibodies are associated with clinical response in patients with melanoma. 30 to 40%> of response rates have been achieved with pembrolizumabTM and nivolumabTM (which are already on the market in the United States of America for patients with metastatic melanoma) as well as promising clinical results in patients with other tumor types: lung cancers, renal cell cancer, Hodgkin lymphomas, gastric cancers, etc.
  • PD-1 and PD-Ll as biomarkers to be used for that characterization, although the number of intra-tumoral PD-1 positive-cells before treatment of patients with melanoma with anti-PD-1 mAb pembrolizumabTM (mAb standing for "monoclonal antibody therapy") is higher in responder patients than in patients who progress under therapy in a series of 46 patients, PD-1 positive cells at baseline has not been found to be a robust predictive marker for response to treatment.
  • PD-Ll is one of the biomarkers being associated with a higher level of response rate to these immunotherapies.
  • expression of PD-Ll alone is neither a very specific, nor sensitive, biomarker.
  • PD-Ll alone is not a stable marker as it can be found positive and negative at the same time in various metastases from the same patient.
  • Second, some patients with negative PD-Ll expressing melanoma can have excellent and durable antitumor responses.
  • PD-Ll expression alone might not be specific biomarker might be that its expression can be induced by various stimuli (including intrinsic PI3K signaling pathway, via a PTEN mutation for example), whereas, it is more likely that its predictive value might be stronger when its expression is induced by the presence of cytokine secreting T cells in the microenvironment.
  • PD-L2 is another ligand for PD-1 but there is no known standardized and reliable way to perform immuno-staining for PD-L2 expression.
  • the present invention aims to improve this situation.
  • the invention proposes a method implemented by computer means for assessing an efficiency of a cure of a cancer disease based on at least one antibody against protein PD-1 and/or its ligand PD-Ll, wherein the method comprises the steps:
  • Counting in said image a number of spots related to said interactions between PD-1 and PD- Ll, and a number of nuclei in said image
  • PLA Proximity Ligation Assay
  • the aforesaid "microscope image” can be more particularly a fluorescence microscope image, or, in another embodiment, a bright field microscope image.
  • said tumor material is an infiltrate. That embodiment shows good statistical characterization results.
  • said tumor material is a tumor tissue.
  • said tumor material includes both an infiltrate and a tumor tissue. That embodiment shows also very good statistical characterization results.
  • a TMB chromogenic revelation is applied to at least tissues of said tumor material (where TMB stands for "3,3',5,5'-Tetramethylbenzidine”). This embodiment enables the observation of pigmented tumor material, including typically melanin tissues.
  • Bajoran purple chromogenic revelation is also used to decrease the background staining.
  • the method according to an embodiment of the invention further comprises a previous step wherein a statistical predictive model is built at first on the basis of:
  • predictive values of said ratio measurements can be assessed in measuring for example the following parameters:
  • assessment of how a patient would react to said treatment can be given according to PD-1 and PD-L1 interaction tests applied on a tumor material of that patient.
  • the predictive model can be applied to test data (ratio measurements of spots number/nuclei number), such tests being performed on a tumor material of a current patient, so as to determine whether that current patient would respond to the treatment or, on the opposite, would be still in progression.
  • data of said estimated ratio are collected from said tumor material and probabilities are estimated on the basis of said collected data to forecast: - a response to the treatment, or
  • these probabilities can be estimated on the basis of a predictive model applied on said collected data.
  • that classification can be made according to at least ratios between number of spots and number of nuclei cells, estimated in respective tumor materials of said patients.
  • the estimated ratios are compared to one or several successive predetermined thresholds in the decision tree algorithm so as to follow one or several respective branch of said decision tree, as explained below with reference to figure 8. It has been observed, in that embodiment at least, that a usual staining characterization method (and not a co-localization assessment method) can be performed further on said respective tumor materials of the patients (staining performed on T cell such as CD8 for example), and a result of that staining characterization method can be combined to the co-localization assessment technique according to the invention.
  • results of that usual staining method can be compared further to at least one secondary threshold defining at least one additional branch of the decision tree, in view to refine patients classification between responders and progressors.
  • the present invention aims also at a drug comprising at least one antibody against PD-1 and/or its ligand, for use in a method of treating cancer in a patient, wherein the patient has been selected to have probabilities to be in response to said drug of higher or equal to a predetermined threshold (for example 50%), said probabilities being determined as defined above.
  • a predetermined threshold for example 50%
  • the present invention aims further at a computer program comprising instructions for performing the method exposed above, when run by a processor.
  • the present invention further aims at a device comprising a computer circuit connected to a camera acquiring at least one microscope image of cells of a tumor material treated for performing a test to assess interactions between PD-1 and PD-L1, such as for example Proximity Ligation Assay (PLA), said computer circuit being arranged to perform the method exposed above.
  • PLA Proximity Ligation Assay
  • the invention proposes therefore a visualization of the interaction between PD-1 and its ligand PD-L1, as a molecular approach.
  • a proximity ligation assay that specifically stains the individual interaction between these two molecules is used so as to visualize the PD-L1 molecules that were engaged in an interaction with PD-1.
  • the PD-l/PD-Ll PLA gives a much cleaner image than the double staining with both antibodies, so as to show co-localization and interaction of the two molecules.
  • each PD-1 molecule that is in close vicinity with its ligand PD-L1 can be visualized as a well-defined colored dot.
  • the usual distance for interaction between the two molecules is in the range between 5 and 20 nm: if such a distance is found between the two molecules and merely in a same 3D plane, then an interaction can be assessed.
  • the double staining with both antibodies the presence of the two proteins can be detected with any information about a possible interaction between these two molecules.
  • Figures 1 to 5 show PD-1 (in black) and PD-L1 (in white) co-staining in a tumor material image (left side of the figures), to be compared with a PLA test performed on a same tumor material (black spots evidencing a co- localization between PD-1 and PD-L1);
  • Figure 6 shows an exemplary embodiment of steps of a method according to the invention
  • Figure 7 shows an exemplary embodiment of a device according to the invention
  • Figure 8 illustrates a decision tree algorithm for classifying patients in a particular embodiment.
  • Proximity Ligation Assay (“in situ PLA”) is a technique that extends the capabilities of traditional immunoassays to include direct detection of proteins, protein interactions and modifications with high specificity and sensitivity. Protein targets can be readily detected and localized with single molecule resolution and objectively quantified in unmodified cells and tissues.
  • the left parts of figures 1 to 5 shows individual molecules PD-1 (in black) and PD-L1 (in white) around nuclei (in light grey). Utilizing only a few cells, sub-cellular events, even transient or weak interactions, are revealed in situ and sub-populations of cells can be differentiated. Within hours, results from conventional co- immuno-precipitation and co-localization techniques can be confirmed.
  • FIG. 1 The right parts of figures 1 to 5 shows such a co-localization between PD-1 and PD-L1 molecules (a black spot for each occurrence of co- localization) around same cells (shown in light grey).
  • PLA probes Species-specific secondary antibodies
  • the DNA strands can interact through a subsequent addition of two other circle- forming DNA oligonucleotides.
  • oligonucleotides After joining of the two added oligonucleotides by enzymatic ligation, they can be amplified via for example rolling circle amplification using a polymerase. During the amplification reaction, several-hundredfold replication of the DNA circle has occurred, and labeled complementary oligonucleotide probes highlight the product. In fluorescence microscopy for instance, the resulting high concentration of fluorescence in each single-molecule amplification product or in bright field microscopy, the resulting high concentration of HRP-converted chromogenic substrate with a counterstaining with hematoxylin is then easily visible as a distinct spot when viewed with a fluorescence or bright field microscope (black spots on the right sides of figures 1 to 5).
  • This detection of the protein interaction may be performed by any conventional means allowing protein interaction detection on tissue section, such as Proximity ligation assay (PLA), Forster or Fluorescence resonance energy transfer (FRET) assays, fluorescence lifetime imaging (FLIM)-FRET, or "dual binders" (DBs), which are bispecific detection agents consisting of two Fab fragment molecules joined by a flexible linker (Van Dieck et al, Chemistry & Biology, 2014).
  • FRET Fluorescence resonance energy transfer
  • FLIM fluorescence lifetime imaging
  • DBs dual binders
  • PKAs Proximity Ligation Assays
  • PLA minus and plus probes (containing the secondary antibodies conjugated with oligonucleotides) were added and incubated during one hour at 37°C. Afterwards, further oligonucleotides were added, allowed to hybridise to the PLA probes, and ligase joined the two hybridised oligonucleotides to a closed circle. The DNA was then amplified (rolling circle amplification), and detection of the amplicons was carried out using a TMB chromogenic revelation in blue with a counterstain in Fast red. Results can be visualized by a scanner OlympusTM VS 120.
  • Automated immuno-histo-chemistry on Ventana Discovery UltraTM platform-epitope retrieval in CC1 buffer is performed during 92 minutes at 95°C.
  • a first staining with anti-PD-Ll antibody, revelation kit anti-rabbit amplification-HQ, enzyme HRP, chromogen DAB, and denaturation is performed with a heating during 8 minutes at 90°C, using a revelation kit.
  • a second staining with anti-PD-1 antibody, revelation kit anti-mouse UltraMAP with amplification, enzyme HRP, chromogen Discovery purple, is then carried out.
  • a first preferred step is the choice of the antibodies for each protein.
  • three different antibodies have been tested for anti-PD-1 and six for anti-PD-Ll in three different antigen retrieval protocols.
  • the integrity of the target complex in tissue samples is a second challenge.
  • PD-1 and PD-L1 are expressed at the membrane of distinct types of cells. Freshly cut tissue sections only have to be used, and the slides must not be exposed to extreme temperature orders to preserve the structure of the cell membranes.
  • Figures 1 to 5 have been obtained on melanin tissues. Care had to be taken in order to differentiate in between dark spots (assessing an interaction between the two molecules of interest) and the melanin tissues, present in melanoma cells (which are physiologically pigmented). To do so, the detection method had to be modified, and, instead of using DAB tags for the detection of the amplicons, TMB chromogenic revelation in blue with a counterstain in Fast red were applied to the tissue samples.
  • the co-staining PD-1 and PD-L1 can visualize both PD-1 and PD-L1 molecules and roughly estimate the distance between them. However, because the tissue section has a sizeable thickness (practically around several micrometers), false positive due to superposition can occur (left sides of figures 1 to 5). When the PLA test is positive, it means by definition that the two molecules are in close vicinity, at a maximal distance of 20 nm one from another (dark spots in right sides of figures 1 to 5).
  • Figures 1 to 5 show a comparison between PD-1 and PD-L1 co-localisation by immunohistochemistry (IHC) in melanoma (left side of the figures) and PD-1/PD-L1 PLA tests performed thereon (right side).
  • IHC immunohistochemistry
  • the PD-1 staining is in DAB (usually brown but tinted in black for the sake of clarity in the left sides of the figures) and the PD-L1 (usual staining in purple, but tinted in white in the left sides of the figures).
  • a PLA test on PD-1/PD-L1 is performed and each black dot in the right sides of the figures 1 to 5 represents the two proteins in close proximity.
  • Figure 1 shows a negative staining in a tumoral sample. IHC is negative (no PD-1 and no PD-L1) and PLA is consequently negative also (no black spot). The patient is in progression.
  • Figure 2 shows a weak staining in infiltrate (from the upper left corner to the lower right corner) and no staining in tumoral sample.
  • PD-1 IHC staining is weak and PD-L1 IHC staining is very weak. The conclusion about the possible interaction between the two proteins is not obvious with these staining.
  • the PLA staining shows few dots and the predicted response is then easier to determine, than the PD- 1 and PD-L1 co-staining taken alone.
  • Figure 3 shows a weak staining in infiltrate and no staining in tumoral sample.
  • PD-1 IHC staining is weak and PD-L1 IHC staining is very weak.
  • the conclusion about the possible interaction between the two proteins is not obvious with these staining.
  • the PLA staining shows few dots and the predicted response is easier to determine than the PD-1 and PD-L1 staining.
  • Figures 4 and 5 show a staining in the germinal center in a lymph node.
  • PD-1 and PD-L1 IHC staining are both strong.
  • the PLA test shows also several dots. Lymph node is then the place of recruitment of both cells PD-1+ and PD-L1+. Lymph nodes are then a good example of application of the invention.
  • a total number of PLA spots (NS) and a total number of nuclei (NN) are evaluated in the total infiltrate.
  • an image contrast optimizer and shape recognition software can be used for identifying the nuclei and the PLA spots, and for counting them.
  • the primary endpoint was the observed clinical response to anti-PD-l/anti-PD-Ll therapy.
  • the effects of the following biomarkers as continuous variables were assessed:
  • Probability for each patient to respond to anti-PD-l/anti-PD-Ll therapy was derived from univariable logistic regression (one biomarker) and from multivariable logistic regression (both the three biomarkers). From the staining results as biomarker, the model classified patients as responders and non- responders: when the staining results corresponded to a predicted probability of clinical response over 50%, patients were classified as predicted responders ; when the staining results corresponded to predicted probability of clinical response below 50%, patients were classified as predicted non- responders.
  • Positive predictive value proportion of responders among predicted positives
  • Negative predictive value proportion of progressors among predicted negative.
  • Exact confidence intervals for each parameter were computed using Clopper-Pearson method.
  • Akaike information criteria (AIC) from the different models were compared to determine the best model (the one with the lowest AIC). Table 1: patients and types of cancer diseases
  • Table 2 probabilities of response predicted by 5 models on the patients of table 1
  • Model 1 PLA only in infiltrate
  • Model 3 PLA only in tumor with infiltrate
  • Model 4 the combination of the PLA in infiltrate, tumor and tumor with infiltrate
  • Patients IGR 1 to 4 are in partial response, while patients IGR 5 to 7 are in progression.
  • Model 3 (having further the lowest AIC).
  • an example of a method according to the invention comprises a first step S 1 5 of selecting, from a tumor material previously extracted from the body of a patient, either:
  • the tumor tissue of the material or
  • the choice of one model among the others may depend on the cancer type (lung, melanoma, liver, etc.).
  • step S1 the tumor 15 material is prepared in step S2 (IHC) so as to perform in step S3 the PLA test.
  • a PLA digital image is then obtained and a subsequent step S4 consists on applying software treatment so as to enhance contrast in the image and, in step S5, recognize in it dark spots and nuclei (for example with a shape recognition algorithm).
  • step S6 the dark spots showing co-localization are counted (NS) and the number of nuclei is further counted (NN) in step S7, so as to calculate the ratio between NS and NN in 20 step S8.
  • steps S3 to S8 can be repeated several times (N) so as to estimate for example an average of the measurement of the ration NS/NN in step S9.
  • the ratio values and/or the average value are inputted in step S10 in the chosen model to determine in step Sl l whether the patient is significantly in response to the treatment or in progression.
  • the method can also be applied to determine whether the patient would respond to the treatment, before the application itself of the treatment based on PD-1 and/or PD-Ll antibodies.
  • the PLA test would then help to determine whether the patient would be in response to that kind of treatment or not, and more precisely to what kind of antibodies, and possibly in which conditions and quantities. Therefore, the present invention aims also at a drug, adapted for a treatment which is
  • the device can comprise a computer circuit CC connected to a camera CAM acquiring from a microscope MIC fluorescence microscope image data of cells of a tumor material TAM treated for performing a test of Proximity Ligation Assay (PLA).
  • PLA Proximity Ligation Assay
  • the computer circuit CC includes typically an input interface IN to receive the image data IM DAT, a storage memory unit MEM to store at least transitorily image data in view to process them (as a working memory), and a processor PROC so as to treat the image data according to steps S4 to Sl l presented above. More particularly, the memory unit MEM further stores computer program instructions (non-transitorily) to be run by the processor PROC. The algorithm of such a computer program can correspond to steps S4 to Sl l commented above.
  • the device can further comprise a screen SCR or a printer to display at least the result of the application of the model in step Sl l, and also a human-machine interface to control the operation of the device (keyboard, touchscreen, mouse, etc.).
  • Anti-PD-Ll antibodies 28.8 (dilution 1 :400), E1L3N (dilution 1 :200), SP142 (here from Spring®, dilution 1 :50), SP263 (dilution 1 :5), El J2J (dilution, 1 :50) and 22C3 (dilution, 1 :3).
  • Anti-PD-1 antibodies Nat 105 (here form from Abeam®, dilution 1 :200) and E18660 (dilution 1 :50)
  • the Proximity Ligation Assays is performed with the SP142 anti-PD-Ll antibody and the Nat 105 anti-PD-1 antibody, as presented in the table below giving a comparison of the specific versus background staining using several anti-PD-1 and anti-PD-Ll antibodies.
  • CD8 IHC is performed on a Ventana Discovery Ultra platform. After deparaffmization, epitope retrieval is performed in CC1 buffer during 32 min at 95°C. Anti-CD8 antibody (clone SP16, Spring Bioscience, M3164) is incubated at 1/100 dilution during 60 min at 37°C. An anti-rabbit UltraMAP HRP detection kit is used for detection and the Discovery Purple is used as a chromogen.
  • Tumor tissues fixed in formalin and embedded in paraffin are obtained in the 4 months prior initiation of an anti-PDl treatment and without any systemic therapy during this period.
  • the percentage of tumor cells is evaluated by a pathologist with haematoxylin and eosin staining. 53 tumor biopsies from 53 patients are selected.
  • RECIST criteria For each patient, the best response during treatment is estimated with the RECIST criteria. They are categorized in three groups: Complete Response (RC), Partial Response (RP) and Progression Disease (PD) and are grouped as shown in the table below presenting the distribution of 52 patients with RECIST criteria.
  • RC Complete Response
  • RP Partial Response
  • PD Progression Disease
  • Two groups are considered more particularly for the model: patients with objective response (Partial Response or Complete Response) and patients with progression (Progressive disease), as shown in the table below presenting distribution of 52 patients specifically for the chosen model.
  • Max CD8 Classical staining method CD8 is still used in the model, as for comparison with PLA, but possibly also as a characterization method combined with PLA in the present example of embodiment.
  • the density of CD8+ infiltrating T-cells is assessed semi-quantitatively by a pathologist using a four categories scale (0, 1 , 2 and 3). Evaluation is performed both at the tumor margin and in the center of the tumor. For each case, the maximum of the two measurements (Max CD8) is used to create the model.
  • a determination of the mean number of dots per nucleus (number of dots in the selected area divided by the number of nuclei detected) representing the quantity of PD1 and PDL1 in close proximity, is made by image analysis using MacBiophotonics ImageJ software. It is assessed in the core of the tumor and in peritumor immune infiltrates, both in areas selected for having the highest density of immune cells. For the model, the measurement into the peritumor immune infiltrate is used in priority, and when not available because of sampling issues, the measurement into the tumor core with immune cell infiltration is used.
  • the C5.0 algorithm (decision tree with nodes) is used.
  • the goal is to create a model that predicts patient response based on several immuno-profiling variables.
  • the decision tree has a flow chart-like structure (figure 8), where each internal node denotes a test on an attribute, each branch represents the outcome of test, and each leaf (or terminal) node holds a class label.
  • C5.0 Node from SPSS is used.
  • This node uses the C5.0 algorithm to build the decision tree from a set of training data, using the concept of information entropy.
  • a C5.0 model works by splitting the sample (e.g. patient response) based on the field (input variables) that provides the maximum information gains. Each subsample defined by the first split is then split again, usually based on a different field, and the process is repeated until the subsamples cannot be split any further. Finally, the lowest-level splits are reexamined, and those that do not contribute significantly to the value of the model are removed or pruned.
  • C5.0 is a commercial and closed-source product (but free of charge source code is available for interpreting and using the decision trees and rule sets it outputs).
  • C5.0 uses a set of models built on subsets of the training data to estimate the accuracy of a model built on the full dataset. This is useful for the present dataset to process because the dataset is too small to be split into traditional training and testing sets.
  • the cross-validation models are discarded after the accuracy estimate is calculated.
  • SPSS Modeler by IBM®
  • no separate model-building step is required. Model building and cross-validation are performed at the same time.
  • rule quest website can be found at http://www.rulequest.com/.
  • variable PLA alone predict as well as variable MaxCD8 alone.
  • Three decision tree models are then tested:
  • the decision tree models appear to be better than the logistic regressions.
  • variable PLA well evaluates the RC (21/23), and is better than the variable Max CD8.
  • chosen threshold are set so as to determine one tree branch to follow rather than another tree branch (examples of thresholds being here 0,008 then, 0,053).
  • PLA results and CD8 characterization results maximum of a usual staining characterization such as CD8, non-applicable for co-localization purpose.
  • the model calculates then the importance of the variables into the prediction, and the PLA appears then to be the most important to predict the response.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Primary Health Care (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Databases & Information Systems (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Data Mining & Analysis (AREA)
  • Hematology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne une méthode mise en œuvre par moyens informatiques (CC) permettant d'évaluer l'efficacité d'une guérison d'une maladie cancéreuse sur la base d'au moins un anticorps dirigé contre la protéine PD-1 et/ou son ligand PD-L1, ladite méthode comprenant les étapes consistant à : obtenir des données d'au moins une image (IM DAT) de microscope (MIC) de cellules de tissus tumoraux (TAM) traités en vue de réaliser un test destiné à évaluer une interaction entre la protéine PD-1 et son ligand PD-L1 dans au moins certaines desdites cellules, compter dans ladite image un certain nombre de points associés aux interactions entre PD-1 et PD-L1, et un certain nombre de noyaux dans ladite image, et estimer un rapport entre ledit nombre de points et ledit nombre de noyaux en vue d'évaluer l'efficacité d'une guérison sur la base d'au moins un anticorps dirigé contre la protéine PD-1 et/ou son ligand PD-L1 sur une maladie cancéreuse à partir de laquelle sont issus lesdits tissus tumoraux.
PCT/EP2016/072477 2015-09-22 2016-09-21 Méthode de cotation pour prédire l'efficacité d'un traitement comprenant des anticorps monoclonaux anti-pd-1 et/ou anti-pd-l1 Ceased WO2017050855A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP15306470.4A EP3147664A1 (fr) 2015-09-22 2015-09-22 Procédé de classement pour prédire l'efficacité d'un traitement avec des anticorps monoclonaux anti-pd-1 et/ou anti-pd-l1
EP15306470.4 2015-09-22
EP16152626.4 2016-01-25
EP16152626 2016-01-25

Publications (1)

Publication Number Publication Date
WO2017050855A1 true WO2017050855A1 (fr) 2017-03-30

Family

ID=57068064

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2016/072477 Ceased WO2017050855A1 (fr) 2015-09-22 2016-09-21 Méthode de cotation pour prédire l'efficacité d'un traitement comprenant des anticorps monoclonaux anti-pd-1 et/ou anti-pd-l1

Country Status (1)

Country Link
WO (1) WO2017050855A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018210927A3 (fr) * 2017-05-16 2019-01-17 Fastbase Solutions Ltd Kits, procédés et leurs utilisations pour détecter des interactions cellule-cellule dans un kit d'échantillons
CN111812326A (zh) * 2020-07-23 2020-10-23 四川携光生物技术有限公司 一种定量检测pd-l1与pd-1结合物含量的试剂盒
CN111883203A (zh) * 2020-07-03 2020-11-03 上海厦维生物技术有限公司 用于预测pd-1疗效的模型的构建方法
JPWO2019208703A1 (ja) * 2018-04-26 2021-04-30 日本電気株式会社 情報処理装置
CN113166815A (zh) * 2019-02-22 2021-07-23 深圳华大生命科学研究院 肠道宏基因组在筛选pd-1抗体阻断剂疗效方面的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014184211A1 (fr) * 2013-05-13 2014-11-20 Institut Gustave Roussy Biomarqueurs pronostiques et prédictifs et applications biologiques associées
WO2015088930A1 (fr) * 2013-12-10 2015-06-18 Merck Sharp & Dohme Corp. Dosage de proximité immunohistochimique pour cellules positives pd-1 et cellules positives de ligand pd dans un tissu tumoral
WO2016073760A1 (fr) * 2014-11-05 2016-05-12 The Regents Of The University Of California Procédés pour stratifier des non-répondeurs à des thérapies qui bloquent l'axe pd1/pdl1

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014184211A1 (fr) * 2013-05-13 2014-11-20 Institut Gustave Roussy Biomarqueurs pronostiques et prédictifs et applications biologiques associées
WO2015088930A1 (fr) * 2013-12-10 2015-06-18 Merck Sharp & Dohme Corp. Dosage de proximité immunohistochimique pour cellules positives pd-1 et cellules positives de ligand pd dans un tissu tumoral
WO2016073760A1 (fr) * 2014-11-05 2016-05-12 The Regents Of The University Of California Procédés pour stratifier des non-répondeurs à des thérapies qui bloquent l'axe pd1/pdl1

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
PAUL C. TUMEH ET AL: "PD-1 blockade induces responses by inhibiting adaptive immune resistance", NATURE, vol. 515, no. 7528, 27 November 2014 (2014-11-27), United Kingdom, pages 568 - 571, XP055247294, ISSN: 0028-0836, DOI: 10.1038/nature13954 *
SODERBERG ET AL., NATURE METHODS, 2006
TUMEH ET AL., NATURE, 2014
VAN DIECK ET AL., CHEMISTRY & BIOLOGY, 2014
WEIBRECHT ET AL., EXPERT REV. PROTEOMICS, 2010

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111492244A (zh) * 2017-05-16 2020-08-04 快百思试剂有限公司 用于检测样品中细胞-细胞相互作用的试剂盒、方法和其用途
CN111492244B (zh) * 2017-05-16 2025-09-02 快百思试剂有限公司 用于检测样品中细胞-细胞相互作用的试剂盒、方法和其用途
WO2018210927A3 (fr) * 2017-05-16 2019-01-17 Fastbase Solutions Ltd Kits, procédés et leurs utilisations pour détecter des interactions cellule-cellule dans un kit d'échantillons
JP2021503594A (ja) * 2017-05-16 2021-02-12 ファストベース ソリューションズ リミテッド 試料における細胞間相互作用を検出するためのキット、方法、およびそれらの使用
JP2022106701A (ja) * 2017-05-16 2022-07-20 ファストベース ソリューションズ リミテッド 試料における細胞間相互作用を検出するためのキット、方法、およびそれらの使用
JP7286627B2 (ja) 2017-05-16 2023-06-05 ファストベース ソリューションズ リミテッド 試料における細胞間相互作用を検出するためのキット、方法、およびそれらの使用
US12326450B2 (en) 2017-05-16 2025-06-10 Fastbase Solutions Sl Kits, methods and their uses for detecting cell-cell interactions in a sample
AU2018268001B2 (en) * 2017-05-16 2024-04-18 Fastbase Solutions Sl Kits, methods and their uses for detecting cell-cell interactions in a sample kits
JPWO2019208703A1 (ja) * 2018-04-26 2021-04-30 日本電気株式会社 情報処理装置
CN113166815B (zh) * 2019-02-22 2024-06-11 深圳华大生命科学研究院 肠道宏基因组在筛选pd-1抗体阻断剂疗效方面的用途
CN113166815A (zh) * 2019-02-22 2021-07-23 深圳华大生命科学研究院 肠道宏基因组在筛选pd-1抗体阻断剂疗效方面的用途
CN111883203A (zh) * 2020-07-03 2020-11-03 上海厦维生物技术有限公司 用于预测pd-1疗效的模型的构建方法
CN111883203B (zh) * 2020-07-03 2023-12-29 上海厦维医学检验实验室有限公司 用于预测pd-1疗效的模型的构建方法
CN111812326A (zh) * 2020-07-23 2020-10-23 四川携光生物技术有限公司 一种定量检测pd-l1与pd-1结合物含量的试剂盒

Similar Documents

Publication Publication Date Title
US20230152326A1 (en) Scoring methods for anti-pd therapy eligibility and compositions for performing same
Mebratie et al. Review of immunohistochemistry techniques: Applications, current status, and future perspectives
KR102502745B1 (ko) 고형종양 진단을 위한 바이오마커 절대 정량 방법 및 장치
Pepe et al. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design
CN112789684B (zh) 用于预测对pd-1轴导向疗法的应答的方法和系统
Ermiah et al. Prognostic value of proliferation markers: immunohistochemical ki-67 expression and cytometric s-phase fraction of women with breast cancer in libya
Kim et al. PD-L1 immunohistochemical assays for assessment of therapeutic strategies involving immune checkpoint inhibitors in non-small cell lung cancer: a comparative study
Uhr et al. Molecular profiling of individual tumor cells by hyperspectral microscopic imaging
WO2017050855A1 (fr) Méthode de cotation pour prédire l'efficacité d'un traitement comprenant des anticorps monoclonaux anti-pd-1 et/ou anti-pd-l1
JP7411667B2 (ja) ステージｉｖの結腸直腸がんにおける免疫細胞浸潤の評価のための方法及びシステム
Ugolini et al. Tumor-infiltrating lymphocyte recognition in primary melanoma by deep learning convolutional neural network
US10444235B2 (en) Systems and methods for treating, diagnosing and predicting the response to therapy of breast cancer
US11579148B2 (en) Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients
Pierceall et al. Strategies for H‐score normalization of preanalytical technical variables with potential utility to immunohistochemical‐based biomarker quantitation in therapeutic reponse diagnostics
US12422435B2 (en) Methods and systems for evaluation of immune cell infiltrate in stage III colorectal cancer
KR102546414B1 (ko) 다중 면역조직화학염색을 이용한 암 환자의 면역 관문 억제제에 대한 치료 반응성을 예측하기 위한 정보를 제공하는 방법
You et al. Prognostic significance of tumor poliovirus receptor and CTLA4 expression in patients with surgically resected non-small-cell lung cancer
JP6675716B2 (ja) 免疫因子を指標とした肺腺癌の予後演算式作成方法と予後推定方法
EP3147664A1 (fr) Procédé de classement pour prédire l'efficacité d'un traitement avec des anticorps monoclonaux anti-pd-1 et/ou anti-pd-l1
García et al. Immunohistochemical analysis of tumour regression grade for rectal cancer after neoadjuvant chemoradiotherapy
US20230062274A1 (en) Methods for Determining the Likelihood of Survival and for Predicting Likelihood of Metastasis in Cancer Patients
CN115552248A (zh) 用于评价肿瘤样品中egfr和egfr配体表达的组织化学系统和方法
Hewitt et al. Validation of proteomic‐based discovery with tissue microarrays
Jasani et al. Implementation of Precision Cancer Diagnostic Test
Blise et al. 39 Spatial single-cell quantitative analyses of human head and neck squamous cell carcinomas

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16775556

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16775556

Country of ref document: EP

Kind code of ref document: A1